Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Adicet Bio ( (ACET) ) has issued an update.
Adicet Bio has initiated the Phase 1 clinical trial of ADI-270, dosing the first patient with metastatic/advanced clear cell renal cell carcinoma (ccRCC). This significant milestone marks the advancement of Adicet’s gamma delta 1 CAR T cell product aimed at addressing solid tumors. With encouraging preclinical data showing potent activity and tumor infiltration, Adicet plans to share preliminary clinical data in the first half of 2025, potentially impacting treatment options for ccRCC, which currently has limited effective therapies.
More about Adicet Bio
Adicet Bio, Inc. is a clinical stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer. The company is advancing a pipeline of ‘off-the-shelf’ gamma delta T cells engineered with chimeric antigen receptors (CARs) to provide durable activity for patients.
YTD Price Performance: -52.65%
Average Trading Volume: 586,850
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $73.78M
Find detailed analytics on ACET stock on TipRanks’ Stock Analysis page.
Trending Articles
- Disney (NYSE:DIS) Cuts Stephanopoulos Pay Post-Trump Settlement
- Ford (NYSE:F) Quality Turns In Surprising Win
- Intel (NASDAQ:INTC) Narrows Down Altera Buyers
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
